Hamzeh Abdul-Hadi

Debiopharm Innovation Fund SA develops, manufactures, and markets diagnostic systems. It seeks to invest in the biotechnology, diagnostics, and pharmaceutical industries with a focus on biomarker development, and large molecule capabilities. The firm mission is to invest in innovative diagnostic companies developing platforms and content to complement in-house diagnostic activities, give insight into cutting-edge diagnostics and facilitate access to new technologies. The company was founded in 1979 and is headquartered in Fribourg, Switzerland.

Debiopharm Innovation Fund SA develops, manufactures, and markets diagnostic systems. It seeks to invest in the biotechnology, diagnostics, and pharmaceutical industries with a focus on biomarker development, and large molecule capabilities. The firm mission is to invest in innovative diagnostic companies developing platforms and content to complement in-house diagnostic activities, give insight into cutting-edge diagnostics and facilitate access to new technologies. The company was founded in 1979 and is headquartered in Fribourg, Switzerland.

Debiopharm Innovation Fund SA develops, manufactures, and markets diagnostic systems. It seeks to invest in the biotechnology, diagnostics, and pharmaceutical industries with a focus on biomarker development, and large molecule capabilities. The firm mission is to invest in innovative diagnostic companies developing platforms and content to complement in-house diagnostic activities, give insight into cutting-edge diagnostics and facilitate access to new technologies. The company was founded in 1979 and is headquartered in Fribourg, Switzerland.

Debiopharm Innovation Fund SA develops, manufactures, and markets diagnostic systems. It seeks to invest in the biotechnology, diagnostics, and pharmaceutical industries with a focus on biomarker development, and large molecule capabilities. The firm mission is to invest in innovative diagnostic companies developing platforms and content to complement in-house diagnostic activities, give insight into cutting-edge diagnostics and facilitate access to new technologies. The company was founded in 1979 and is headquartered in Fribourg, Switzerland.

Debiopharm Innovation Fund SA develops, manufactures, and markets diagnostic systems. It seeks to invest in the biotechnology, diagnostics, and pharmaceutical industries with a focus on biomarker development, and large molecule capabilities. The firm mission is to invest in innovative diagnostic companies developing platforms and content to complement in-house diagnostic activities, give insight into cutting-edge diagnostics and facilitate access to new technologies. The company was founded in 1979 and is headquartered in Fribourg, Switzerland.